Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in the Denali team with a proposal to spin out the small-molecule drugs with ...

William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its target price decreased by stock analysts at JPMorgan Chase & Co. from $28.00 to $24.00 in a research report issued on Tuesday,Benzinga ...

Denali Therapeutics (NASDAQ:DNLI) shares plunged 7% after its ALS treatment, DNL343, failed to meet its primary endpoint in a phase 2/3 study, according to topline results. The primary endpoint ...

In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report), with a price ...

William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for neurodegenerative diseases. The analyst highlights that Denali is ...

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging ...